U.S., April 2 -- ClinicalTrials.gov registry received information related to the study (NCT06903754) titled 'ISGLT2 in Patients Without DM With Acute MI' on March 22.
Brief Summary: This study will evaluate the effect of ISGLT2 (Dapagliflozin or Empalgliflozin), administered once daily in addition to standard of care treatments for non-diabetic patients with myocardial infarction (MI) treated with PCI, on hospitalization for heart failure, readmissions for acute coronary syndrome and all-cause mortality.
Study Start Date: Oct. 01, 2021
Study Type: OBSERVATIONAL
Condition:
Acute Coronary Syndromes
Heart Failure
Intervention:
DRUG: With ISGLT2
Patients for whom we will prescribe ISGLT2
Recruitment Status: ACTIVE_NOT_RECRUITING
Spons...